Clinical Trials' Weight Loss Drug Relevance in U.S

JAMA Network

About The Study: This study estimates that approximately one-third of U.S. adults without diabetes who were eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) were excluded from clinical trials supporting these medications' safety and effectiveness. Until there is evidence from high-quality postmarketing studies, the FDA should consider updating labeling to advise caution on generalizing the safety and effectiveness of GLP-1 and GLP-1/GIP to populations excluded from pivotal trials.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.